Powered by
-
NVAX Stock Chart
Historical NVAX Prices
NOVAVAX RG Stock Analysis
Rating: Buy
Total Grade: B
Analysis Breakdown
| NVAX Stock Grade: | B |
| Fundamental Grade: | B |
| Quantitative Grade: | B |
| NVAX Earnings | |
| Earnings Growth: | C |
| Earnings Momentum: | C |
| Earnings Surprises: | D |
| Analyst Earnings Revisions: | A |
| NVAX Financial Information | |
| Sales Growth: | A |
| Operating Margin Growth: | C |
| Cash Flow: | F |
| Return on Equity: | A |
NOVAVAX RG Stock: Weekly View
| This Week: | B |
|---|---|
| Last Week: | B |
| Two Weeks Ago: | B |
NVAX Stock predictions, Articles, and NOVAVAX RG News
- From InvestorPlace
- From the Web
-
3 Penny Stocks Poised for Growth the Rest of 2018 - June 13, 2018
These penny stocks are well-positioned for improving market conditions and possibly growth beyond penny stock status in the second half of 2018 and beyond. Continue…
-
3 Biotech Stocks That Will Thrive Amid Market Instability - April 19, 2018
The drugs/biotech sector has been down since the past month, reeling under broader market pressures. Only a few good stocks however, remain out of this rut. Com.... Continue…
-
5 Big Biotech Stocks to Buy Under $10 - March 20, 2018
Small biotech stocks can pack a wallop. Here are five biotech stocks that have prospects bigger than their share prices. Continue…
-
Novavax (NVAX) Stock Upgraded to Buy - January 23, 2018
As one of the 657 companies in the GICS Health Technology sector Novavax Inc (NASDAQ:NVAX) is a constituent of the 337 company Biotechnology GICS industry group within this sector. NVAX has a market value of $0.6 billion which is in the top half of its industry group. Portfolio Grader's current ranking for NVAX puts it 107 among the 337 companies in this industry group, putting it in the second quartile; in the top half of the sector with a ranking of 213 among the 657 companies in the sector, and number 1,498 in the nearly 5,000 company Portfolio Grader universe. Continue…
-
Earnings Visibility Hamper Novavax (NVAX) Rating - January 11, 2018
Novavax Inc (NASDAQ:NVAX) ranks in the upper half of its industry group, Biotechnology, and in the upper half of its sector group, Health Technology, with a market value of $0.4 billion. From an investment attractiveness vantage point, NVAX is ranked in the top half of the sector with a ranking of 264 among the 656 companies in the sector; the ranking for NVAX by Portfolio Grader places it 127 among the 337 companies in this industry group, giving it an above-average position and number 1,942 in the 5000 company Portfolio Grader company universe. Continue…
-
40 Biotechnology Stocks to Sell Now - December 12, 2016
This week, the overall grades of 40 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell"). Continue…
-
40 Biotechnology Stocks to Sell Now - December 5, 2016
The overall ratings of 40 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell"). Continue…
-
3 Battered Biotechs That Could Turn Things Around - September 23, 2016
Biotechs like NVAX, GERN and RGLS have made a name for themselves for all the wrong reasons, but they also have a chance at redemption. Continue…
-
NVAX Stock: Novavax Attempts to Claw Its Way Back From the Pits - September 22, 2016
Novavax (NVAX) stock is an absolute wild card, but it sure is scrappy. Regardless, it's bound to see a shift in analyst expectations soon. Continue…
-
Hottest Manufacturing Stocks Now – FATE OCRX AEGR WVE - September 22, 2016
The following stocks were the biggest movers and shakers in the Manufacturing sector today. Continue…
